14 results on '"Sun, K."'
Search Results
2. P-409 Outcomes of patients with unresectable hepatocellular carcinoma who developed an infection while receiving atezolizumab
3. P-69 Efficacy and safety of surufatinib in intrahepatic cholangiocarcinoma: Preliminary results of a real-world study
4. 1507P A retrospective study of angiotensin-converting enzyme inhibitors or beta-blockers to prevent trastuzumab-induced cardiotoxicity
5. 1843P Electro-acupuncture for quality of life in gastric cancer patients undergoing adjuvant chemotherapy
6. 1646P Apatinib for treatment of inoperable metastatic or locally advanced chondrosarcoma: What we can learn about the biological behavior of chondrosarcoma from a multicenter study
7. 1644P Dynamic changes in quality of life and Q-TWiST analysis for Ewing sarcoma patients following anlotinib and irinotecan: A combination of phase Ib and II trial
8. Clinical confirmation of higher exposure to niraparib in tumour vs plasma in patients with breast cancer
9. A first-in-human study of a novel monoclonal antibody INCSHR01210 directed against programmed cell death protein 1 (PD-1) in patients with advanced or metastatic cancer
10. 231P Nomogram to predict prognosis in thoracic esophageal squamous cell carcinoma after neoadjuvant radiotherapy or chemoradiotherapy
11. 211P - Clinical confirmation of higher exposure to niraparib in tumour vs plasma in patients with breast cancer
12. 1182P - A first-in-human study of a novel monoclonal antibody INCSHR01210 directed against programmed cell death protein 1 (PD-1) in patients with advanced or metastatic cancer
13. 1765P Second-line targeted therapy patterns and outcomes of advanced gastrointestinal stromal tumor: A prospective, multicentered real-world study.
14. 1763P Initial tumour size and residual mitotic count post-neoadjuvant imatinib linked to shorter relapse-free survival in GIST patients.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.